gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · BSXHealthcareSurgical Instruments

Boston Scientific Corp. (BSX)

$45.82+5.33%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$43.50▼ 55.88% in range
Nov 3, 2025Low $41.58 · High $104.98Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Boston Scientific closed at $45.82 on Nov 4, up 5.33%, 56.4% below its 52-week closing high. Volume of 34.6M shares was 1.79× its 20-day average (above normal).

Split-adjusted performance: +8.6% over one month, -18.2% over six months, -53.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $5.14B, up 1.4% from a year earlier, with a net margin of 11.3%.

Short interest was 40.7M shares at the Oct 15 settlement, down 1.7% from the prior report (2.8% of float, 2.6 days to cover).

Market cap$66.40B1.45B shares
Revenue · quarter$5.14B+1.4% YoY
Diluted EPS$0.40−21.6% YoY
P/E · TTM19.0×P/S 3.2×
Net margin11.3%Gross 66.7%
Dividend yieldNone
52-week range41.58 – 104.98−56.4% from high
Volume34.6M1.79× 20-day avg
Volatility · 60d37.9%Annualised
Short % of float2.8%2.6 days to cover
Net cash-$11.34BCash $609.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.0%1M +8.6%3M −7.1%6M −18.2%YTD −51.9%1Y −53.5%3Y −8.5%5Y +4.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum39
Revenue growth26
Net margin82
Value (low P/E)77
Size98

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short40.7M−1.7% vs prior
Days to cover2.6Settled Oct 15
% of float2.8%
Short vol. 10d36.0%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BSXBoston Scientific$45.82+5.33%−18.2%+1.4%11.3%19.0$66.40B
BDXBecton, Dickinson and$209.19+5.56%+44.5%+5.4%7.6%60.6$56.98BCompare
MMM3M$193.95+9.55%+32.4%+1.0%20.9%28.3$100.02BCompare
MDLNMedline$40.35+18.36%−4.0%—0.8%—$35.40BCompare
SYKStryker$339.65+9.37%+16.2%+7.6%11.5%36.0$130.28BCompare
RMDResMed$240.51+5.91%+14.7%+5.9%29.6%21.2$33.83BCompare
DXCMDexCom$88.48+6.64%+46.6%+11.2%20.5%33.3$33.00BCompare
WSTWest Pharmaceutical Services$408.78+0.44%+30.8%+8.7%24.5%44.6$28.48BCompare
SOLVSolventum$89.35+5.42%+25.9%+2.2%4.2%10.6$15.21BCompare

News about Boston Scientific

All news →
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?Zacks Investment Research · 5d ago▼ NegativeBoston Scientific: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Oct 29, 2026▼ NegativeStock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack ImpactThe Motley Fool · Oct 28, 2026▼ NegativeBSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock DownZacks Investment Research · Oct 28, 2026▼ NegativeBoston Scientific (BSX) Q3 Earnings Match EstimatesZacks Investment Research · Oct 28, 2026▼ Negative

Quick answers

What does Boston Scientific do?
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence.
What is BSX's market cap?
$66.40B, based on the Nov 4 close of $45.82.
What is BSX's P/E ratio?
19.0× trailing-twelve-month earnings of $3.50B.
Does Boston Scientific pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BSX is sold short?
40.7M shares, 2.8% of float, as of Oct 15, 2026.
What sector is BSX in?
Healthcare, in the Surgical Instruments industry.

About Boston Scientific

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

HQ: Marlborough, MA59,000 employeesListed May 18, 1992bostonscientific.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology